Digital Diet Tracking in GLP-1 Therapy: UK Feasibility Study Tests Three Tools for Obesity Management

References

1. 1.Australian Digital Health Agency. (2023). National Digital Health Strategy and Framework for Action 2023-2028. Australian Government. https://www.digitalhealth.gov.au/about-us/strategies-and-plans/national-digital-health-strategy-and-framework-for-action-2023-2028
2. 2.Craig, P., Dieppe, P., Macintyre, S., Michie, S., Nazareth, I., & Petticrew, M. (2008). Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ, 337, a1655. https://doi.org/10.1136/bmj.a1655
3. 3.Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. https://doi.org/10.1016/S0140-6736(21)00213-0
4. 4.King's College London. (2024). A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment. ClinicalTrials.gov. NCT07194317. https://clinicaltrials.gov/study/NCT07194317
5. 5.Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., Rodrigues, A. M., Rehackova, L., Adamson, A. J., Sniehotta, F. F., Mathers, J. C., Ross, H. M., McIlvenna, Y., Stefanetti, R., Trenell, M., ... Taylor, R. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet, 391(10120), 541-551. https://doi.org/10.1016/S0140-6736(17)33102-1
6. 6.Rubino, D., Abramo, A., Erondu, N., Gantz, I., Maloney, A., Kolotkin, R. L., Fujioka, K., Kumar, S., Bharmal, M., Liao, R., Pi-Sunyer, X., & Heymsfield, S. B. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14), 1414-1425. https://doi.org/10.1001/jama.2021.3224
7. 7.Thompson, F. E., & Subar, A. F. (2017). Dietary assessment methodology. In A. M. Coulston, C. J. Boushey, M. G. Ferruzzi, & L. M. Delahanty (Eds.), Nutrition in the Prevention and Treatment of Disease (4th ed., pp. 5-48). Academic Press. https://doi.org/10.1016/B978-0-12-802928-2.00001-1
8. 8.Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183